Ritonavir Patent Expiration
Ritonavir is Used for treating HIV infection in combination with other antiretroviral agents. It was first introduced by Abbvie Inc
Ritonavir Patents
Given below is the list of patents protecting Ritonavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Norvir |
US8470347 (Pediatric) | Self-emulsifying active substance formulation and use of this formulation | Mar 17, 2027 | Abbvie |
| Norvir | US8470347 | Self-emulsifying active substance formulation and use of this formulation |
Sep 17, 2026
(Expired) | Abbvie |
| Norvir |
US8268349 (Pediatric) | Solid pharmaceutical dosage form |
Feb 25, 2025
(Expired) | Abbvie |
| Norvir |
US8399015 (Pediatric) | Solid pharmaceutical dosage form |
Feb 25, 2025
(Expired) | Abbvie |
| Norvir |
US8691878 (Pediatric) | Solid pharmaceutical dosage form |
Feb 25, 2025
(Expired) | Abbvie |
| Norvir | US8268349 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Norvir | US8399015 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Norvir | US8691878 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Norvir |
US7364752 (Pediatric) | Solid dispersion pharamaceutical formulations |
May 10, 2021
(Expired) | Abbvie |
| Norvir |
US7141593 (Pediatric) | Pharmaceutical formulations |
Nov 22, 2020
(Expired) | Abbvie |
| Norvir |
US7432294 (Pediatric) | Pharmaceutical formulations |
Nov 22, 2020
(Expired) | Abbvie |
| Norvir | US7364752 | Solid dispersion pharamaceutical formulations |
Nov 10, 2020
(Expired) | Abbvie |
| Norvir | US7141593 | Pharmaceutical formulations |
May 22, 2020
(Expired) | Abbvie |
| Norvir | US7432294 | Pharmaceutical formulations |
May 22, 2020
(Expired) | Abbvie |
| Norvir |
US7148359 (Pediatric) | Polymorph of a pharmaceutical |
Jan 19, 2020
(Expired) | Abbvie |
| Norvir | US7148359 | Polymorph of a pharmaceutical |
Jul 19, 2019
(Expired) | Abbvie |
| Norvir |
US6232333 (Pediatric) | Pharmaceutical composition |
May 07, 2018
(Expired) | Abbvie |
| Norvir | US6232333 | Pharmaceutical composition |
Nov 07, 2017
(Expired) | Abbvie |
| Norvir |
US6037157 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Abbvie |
| Norvir |
US6703403 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Abbvie |
| Norvir | US6037157 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Norvir | US6703403 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Norvir |
US5648497 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 15, 2015
(Expired) | Abbott |
| Norvir |
US5648497 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 15, 2015
(Expired) | Abbvie |
| Norvir |
US5635523 (Pediatric) | Retroviral protease inhibiting compounds |
Dec 03, 2014
(Expired) | Abbott |
| Norvir |
US5484801 (Pediatric) | Pharmaceutical composition for inhibiting HIV protease |
Jul 28, 2014
(Expired) | Abbvie |
| Norvir | US5648497 | Retroviral protease inhibiting compounds |
Jul 15, 2014
(Expired) | Abbott |
| Norvir | US5648497 | Retroviral protease inhibiting compounds |
Jul 15, 2014
(Expired) | Abbvie |
| Norvir | US5635523 | Retroviral protease inhibiting compounds |
Jun 03, 2014
(Expired) | Abbott |
| Norvir |
US5948436 (Pediatric) | Pharmaceutical composition |
Mar 13, 2014
(Expired) | Abbott |
| Norvir |
US5948436 (Pediatric) | Pharmaceutical composition |
Mar 13, 2014
(Expired) | Abbvie |
| Norvir |
US5541206 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbott |
| Norvir |
US5541206 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Norvir |
US5635523 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Norvir |
US5674882 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Norvir | US5484801 | Pharmaceutical composition for inhibiting HIV protease |
Jan 28, 2014
(Expired) | Abbvie |
| Norvir | US5948436 | Pharmaceutical composition |
Sep 13, 2013
(Expired) | Abbott |
| Norvir | US5948436 | Pharmaceutical composition |
Sep 13, 2013
(Expired) | Abbvie |
| Norvir | US5541206 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbott |
| Norvir | US5541206 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
| Norvir | US5635523 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
| Norvir | US5674882 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
Ritonavir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ritonavir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 | Pfizer | NA |
TERMINATED
(Aug 1, 2026)
| PHASE1 |
| A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) | Daré Bioscience, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| First in Human Study of TLC-ART 101 (ACTU 2001) | University of Washington | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |
| Lopinavir/Ritonavir in PLWH With High-Grade AIN | University of Wisconsin, Madison | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women | Pfizer | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms | Kanecia Obie Zimmerman | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |